Schrödinger to Present at Morgan Stanley Global Healthcare Conference
SDGRNEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference. The live presentation will take place on Monday, September 8, 2025 at 11:30 a.m. E.T. The live webcast can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery wi
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SDGRNEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 15, 2025, the company granted restricted stock units (RSUs) with respect to 1,875 shares of the company’s common stock to two newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement t
Schrödinger Announces Discontinuation of SGR-2921 Program
SDGRNEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the discontinuation of the clinical development program for SGR-2921, its CDC7 inhibitor, which was being evaluated in a Phase 1 dose-escalation study in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. Despite early evidence of monotherapy activity observed in the Phase 1 study, based on the profile observed to date, including two emergent events where SGR-2921 was consid
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
SDGRNEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. (“Schrödinger” or the “Company”) (NASDAQ: SDGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SDGRNEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on June 13, 2025, the company granted restricted stock units (RSUs) with respect to 10,290 shares of the company’s common stock to five newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement t
Schrödinger Reports 22% Response Rate in Early Trial for Drug-Resistant B-Cell Cancers
SDGRSchrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress
SDGRMILAN--(BUSINESS WIRE)--Schrödinger announces encouraging initial clinical data from its ongoing Phase 1 dose-escalation study of SGR-1505.
Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress
SDGRMILAN--(BUSINESS WIRE)--Schrödinger announces encouraging initial clinical data from its ongoing Phase 1 dose-escalation study of SGR-1505.
Schrödinger Appoints Richie Jain As CFO Succeeding Geoffrey Porges Who Will Remain As Advisor Through June 6 For Smooth Transition
SDGRSchrödinger Restructures Operations To Reduce Workforce And Costs; Workforce Reduction To Affect 60 Employees, 7% Of Staff; Restructuring To Incur $3M In Charges
SDGRSchrödinger To Present Phase 1 Clinical Data On MALT1 Inhibitor SGR-1505 At EHA Annual Congress And International Conference On Malignant Lymphoma
SDGRSchrodinger Software revenue growth is expected to range from 10% to 15%; Drug discovery revenue is expected to range from $45 million to $50 million.
SDGRSchrodinger Q1 Adj. EPS $(0.64) Beats $(0.75) Estimate, Sales $59.55M Beat $54.65M Estimate
SDGRKeybanc Maintains Overweight on Schrodinger, Raises Price Target to $32
SDGRPiper Sandler Maintains Overweight on Schrodinger, Lowers Price Target to $45
SDGRSchrodinger Sees FY2025 Sales $243.402M-$257.420M vs $265.80M Est
SDGRSchrodinger Q4 Adj $(0.24) Beats $(0.42) Estimate, Sales $88.30M Beat $83.20M Estimate
SDGRSchrödinger Unveils Its Strategic Priorities For 2025; Expands Research Collaboration With Otsuka; Expects To Receive Upfront Payment Of $150M From Novartis In Q1 Of 2025
SDGRSchrödinger Wins Additional $9.5M From Bill & Melinda Gates Foundation
SDGRMorgan Stanley Maintains Equal-Weight on Schrodinger, Raises Price Target to $39
SDGRRecap: Schrodinger Q1 Earnings
SDGRSchrodinger (NASDAQ:SDGR) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
Schrodinger beat estimated earnings by 7.69%, reporting an EPS of $-0.48 versus an estimate of $-0.52.
Schrodinger Sees FY22 Sales $161M-$181M Vs. $172.25M Est.
SDGRSchrodinger Q1 EPS $(0.48) Beats $(0.52) Estimate, Sales $48.70M Beat $34.57M Estimate
SDGR